The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans
Joyce James, Stuart Mair, Walter Doll, Erik Sandefer, David Wurtman, Alan Maurer, Adam M Deane, M Scott Harris
Neurogastroenterology & Motility | WILEY | Published : 2020
BACKGROUND: Ulimorelin, a small molecule ghrelin agonist and prokinetic agent, was effective in animal models of gastroparesis and delayed transit. However, employing once daily administration, it failed in clinical trials of postoperative ileus (POI), a condition in which colonic motility recovers last. The aim of this study was to evaluate drug dosing and regional differences in drug activity between stomach and colon. METHODS: Gastric emptying was assessed by scintigraphy in healthy adults at single doses of 600-1200 µg kg-1 and multiple doses of 80-600 µg kg-1 Q8H for 7 days. Colonic motility was assessed by 7-region scintigraphic analysis at a dose of 600 µg kg-1 for 2 days. The primary..View full abstract
This study was funded by Lyric Pharmaceuticals. The study sponsor was primarily responsible for the study design, collection, analysis, and interpretation of the data.